Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04930653 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

StatusRecruiting
PhasePhase 2
Started2022-10-19
View on ClinicalTrials.gov ↗

Amendment history

2026-08-31
Study Status, Contacts/Locations v14
Recruitment resumed after suspension
Reason stoppedAccrual Goal Met→not stated
Study sitesdetails revised at 3 of 3 sites
2026-08-11
Recruiting→Suspended Study Status, Contacts/Locations v13
Recruitment suspended: Accrual Goal Met
Trial statusRecruiting→Suspended
Study sitesdetails revised at 3 of 3 sites
2025-10-10
Study Status, Contacts/Locations v12
Primary completion date2026-01-13→2028-06-15
Completion date2026-01-13→2028-06-15
Study sites2→3
2025-06-02
Study Status v11
Primary completion date2025-05-16→2026-01-13
Completion date2025-05-16→2026-01-13
2025-02-17
Study Status, Contacts/Locations v10
Study sites1→2
Show 9 earlier versions
2024-02-14
Study Status v9
Primary completion date2023-11-15→2025-05-16
Completion date2023-11-15→2025-05-16
2023-06-14
Study Status, Contacts/Locations v8
Study sitescontacts updated at 1 of 1 site
2023-03-14
Active, Not Recruiting→Recruiting Study Status, Study Design, Contacts/Locations v7
Trial statusActive, Not Recruiting→Recruiting
Enrollment target1→34
Study sitesdetails revised at 1 of 1 site
2022-12-08
Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v6
Trial statusRecruiting→Active, Not Recruiting
Start dateestimated 2022-11-30→confirmed 2022-10-19
Enrollment targetestimated 24→confirmed 1
Study sitesdetails revised at 1 of 1 site
2022-09-08
Study Status v5
Start date2022-07-30→2022-11-30
2022-05-19
Study Status v4
Start date2022-04-30→2022-07-30
2022-02-28
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v3
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2023-12-31→2023-11-15
Completion date2023-12-31→2023-11-15
Start date2021-12-15→2022-04-30
Study sitesdetails revised at 1 of 1 site
2021-10-29
Study Status v2
Start date2021-10-15→2021-12-15
2021-08-10
Study Status v1
Start date2021-07-15→2021-10-15
2021-06-11
Original filing
This phase II trial studies the effect of extracorporeal photopheresis (ECP) and mogamulizumab in treating patients with erythrodermic cutaneous T cell lymphoma (CTCL), a type of skin lymphoma. CTCL is a rare type of cancer that begins in the white blood cells called T cells. Erythrodermic is a widespread red rash that may cover most of the body. ECP is a medical treatment that removes blood with a machine, isolates white blood cells and exposes them to ultra violet light, then returns the cells to the body. Mogamulizumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving mogamulizumab with ECP may work together to kill the tumor cells directly (with mogamulizumab) and boost immune response to cancer (with ECP).
Trial Details
NCT Number NCT04930653
Lead Sponsor City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Conditions Folliculotropic Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Transformed Mycosis Fungoides
Enrollment 34 participants
Start Date 2022-10-19
Primary Completion 2028-06-15 (estimated)
Study Completion 2028-06-15 (estimated)
Updated on ClinicalTrials.gov 2026-09-02